Ipilimumab
Based on 5 publication(s) in Google Scholar
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.
For research use only. We do not sell to patients.
- Purity : 99.83%
- CAS No.: 477202-00-9
- Molecular Weight:145.38 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
CTLA4
In Vitro
Ipilimumab inhibits CTLA-4, allowing the T cell immune response to be reactivated against tumor cells. Ipilimumab can promote antitumor activity as a single agent or in combination with cytokines, chemotherapy, or vaccines[1].
Ipilimumab (0, 5 or 50 μg/ mL, 6 days) alone can enhance IL-2 production and in combination with nivolumab stimulate higher IL-2 release in peripheral blood mononuclear cells (PBMC). And the combination of ipilimumab and nivolumab treatment synergistically enhances effector and memory T-cell responses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Jurkat cells labeling CTLA4 with Ipilimumab (HY-P9901, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control. -
Ipilimumab has a significant CDC effect on CHOK1-human CTLA4 cells in a dose-dependent manner.The EC50 for this effect is 604 ng/mL.
Product Details
-
CAS No. 477202-00-9
-
Accession P16410
-
Synonyms MDX-010; BMS-734016
-
Molecular Weight 145.38 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.83%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3. [Abstract]2024 Mar 22;15(1):2567. PMID: 38519469 -
Am J Hematol
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts. [Abstract]2024 Oct;99(10):1939-1950. PMID: 38953347
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 mg/kg; i.p.; once a week for 4 weeks) treatment dramatically decreased granulocyte numbers in the spleen (SP) and bone marrow (BM) as well as monocyte numbers in the bone marrow (BM) of PDX mice.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 mg/kg; i.p.; once a week for 4 weeks) enabled detection of human CD3+ T cells exclusively in the spleen (SP) and bone marrow (BM) of treated animals.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 mg/kg; i.p.; once a week for 4 weeks) decreased CD34+ cells among human CD45 + CD3- cells in bone marrow (BM) of PDX mice.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 μg/mL) showed efficacy in reactivating MF T-cell response in the presence of myeloid cells, as demonstrated by the increased percentage of OX40-positive CD3+CD8+ T cells compared to isotype control-treated samples.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 μg/mL) elicited a significant T cell-mediated killing of CD14+ and CD15+ myeloid populations in the CD3- live cells fraction (0.41 and 0.27 fold reduction, respectively).
-
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Hum Mutat
Combined Nivolumab and Ipilimumab Therapy Promotes Immune-Mediated Cardiomyocyte Apoptosis Through TLR4-Myd88-NF- Κ b-Driven Activation of the NLRP3 Inflammasome. [Abstract]2026 Apr 23:2026:8506248. PMID: 42040892 -
Purity & Documentation
References
[1]. Movva S, et al. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41. [Content Brief]
[2]. Mark J Selby, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e0161779. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)